Core Viewpoint - L3Harris Technologies, Inc. (NYSE:LHX) is highlighted as a must-buy dividend stock due to its strong financial performance and consistent dividend payouts [2][4]. Group 1: Company Overview - L3Harris is a major defense contractor specializing in advanced communication, surveillance, space, and missile defense systems, primarily serving US government agencies and allied military forces [2][3]. - The company has strengthened its space business in 2023 by acquiring Aerojet Rocketdyne, enhancing its capabilities in launching large payloads into space [3]. Group 2: Financial Performance - L3Harris boasts a 23-year track record of dividend growth, making it an attractive option for dividend-seeking investors [4]. - The current quarterly dividend is $1.20 per share, with a dividend yield of 1.61% as of October 9 [4].

Core Insights - Exxon Mobil Corporation (NYSE:XOM) has achieved an annual earnings growth rate of approximately 30% over the last five years, with cash flow increasing at a CAGR of around 15% during the same period [1] - The company aims to generate an additional $20 billion in earnings and $30 billion in cash flow by 2030 [1] - Exxon Mobil has distributed over $125 billion in dividends and buybacks in the past five years, maintaining a record of raising dividends for 42 consecutive years, positioning it among the top 10 S&P Dividend Stocks [2] Company Overview - Exxon Mobil is one of the largest integrated fuels, lubricants, and chemical companies globally, with operations and product marketing across six continents [3] - The company explores for oil and natural gas worldwide, showcasing its extensive reach in the energy sector [3]

Group 1 - Bristol-Myers Squibb Company (BMY) is recognized as one of the best stocks for a dividend stock portfolio due to its consistent dividend growth over 16 consecutive years [4] - The company declared a quarterly dividend of $0.62 per share on September 17, maintaining its previous dividend level, resulting in a dividend yield of 5.42% as of September 18 [4] - BMY focuses on developing treatments for various diseases, including cancer and blood disorders, with notable products like Opdivo and Eliquis, and is expanding its pipeline in cell therapy and immunology [2][3] Group 2 - In recent years, BMY has aimed to grow its "Growth Portfolio" by launching new medicines and enhancing its global presence, while also acquiring assets through partnerships [3] - A significant challenge for the company is managing revenue declines from its "Legacy Portfolio" as older drugs face patent expirations and generic competition [3] - To counteract these challenges, BMY prioritizes research and development, builds strategic collaborations, and navigates regulatory and pricing pressures in international markets [3]